866-997-4948(US-Canada Toll Free)

Bipolar Disorder - Drug Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Nov 2010

Category :

Therapeutic Area

No. of Pages : 49 Pages


GlobalData, the industry analysis specialist, has released its new report, Bipolar Disorder Drug Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Bipolar Disorder market. The report identifies the key trends shaping and driving the global Bipolar Disorder market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bipolar Disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData estimates that the global Bipolar Disorder market was valued at $4.4 billion in 2009 and is forecast to decline by 10% annually for the next seven years to reach $1.9 billion by 2017. This modest decline in the forecast is primarily attributed to the patent expiry of all the major marketed products, the availability of the generic versions of those products, and the strong competition in the market. The Bipolar Disorder market is primarily formed of generic and off-label drugs and has very few approved drugs which fall in the major therapeutic categories such as Dopamine and Serotonin Antagonist and Sodium and calcium channel inhibitors. 

Scope

The report provides information on the key drivers and challenges of the Bipolar Disorder market. Its scope includes: 

  • Annualized global Bipolar Disorder market revenues data from 2001 to 2009, forecast for eight years to 2017. Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Dopamine Receptor Antagonist, Neuroprotectants, Sodium Channel Inhibitors, Glutamate receptor antagonist, Selective Serotonin Reuptake Inhibitors and the like.
  • Analysis of the current and future competition in the global Bipolar Disorder market. Key market players covered are Gedeon Richter Plc, Dainippon Sumitomo Pharma Co., Ltd. Cephalon, Inc. and Janssen Pharmaceutica.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Bipolar Disorder therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Bipolar Disorder market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Bipolar Disorder market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Bipolar Disorder market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Bipolar Disorder: Introduction 6
2.1 GlobalData Pipeline Report Guidance 7

3 Bipolar Disorder: Market Characterization 8
3.1 Overview 8
3.2 Bipolar Disorder Market Size 8
3.3 Bipolar Disorder Market Forecast and CAGR 9
3.4 Drivers and Barriers for the Bipolar Disorder Market 10
3.4.1 Drivers for the Bipolar Disorder Market 10
3.4.2 Barriers for the Disorder Market 10
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 12

4 Bipolar Disorder Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Bipolar Disorder Market 14
4.3.1 Abilify (Aripiprazole) 14
4.3.2 Symbyax (Olazapine and fluoxetine Hcl) 15
4.3.3 Geodon (Ziprasidone Hydrochloride) 16
4.3.4 Zyprexa (olazapine) 17
4.3.5 Equetro (carbamazepine) 18
4.3.6 Seroquel (Quetiapine Fumarate) 19
4.3.7 Saphris (SYNCREST, ORG-5222, Asenapine) 21
4.4 Major Marketed Products Comparison in the Bipolar Disorder Market 22
4.5 Key Takeaway 23

5 Bipolar Disorder Market: Pipeline Assessment 24
5.1 Overview 24
5.2 Strategic Pipeline Assessment 24
5.2.1 Technology Trends Analytical Framework 24
5.3 Bipolar Disorder Therapeutics Promising Drugs under Clinical Development 26
5.4 Molecule Profile for Promising Drugs Under Clinical Development 26
5.4.1 Lurasidone (SM-13496) 26
5.4.2 Nuvigil (armodafinil) 27
5.4.3 Invega (Paliperidone) 28
5.4.4 RGH-188 (Cariprazine) 29
5.5 Bipolar Disorder Therapeutics Market Clinical Pipeline by Therapeutic Class 30
5.6 Bipolar Disorder Disease Pipeline Pipeline by Clinical Phases of Development 30
5.7 Bipolar Disorder Therapeutics Phase III Clinical Pipeline 31
5.8 Bipolar Disorder Therapeutics Phase II Clinical Pipeline 31
5.8.1 Bipolar Disorder Therapeutics Phase I Clinical Pipeline 32
5.8.2 Bipolar Disorder Therapeutics Preclinical Pipeline 32
5.9 Key Takeaway 32

6 Bipolar Disorder Market: Implications for Future Market Competition 33

7 Bipolar Disorder Market: Future Players 34
7.1 Introduction 34
7.2 Janssen Pharmaceutica 34
7.2.1 Company Overview 34
7.2.2 Major Products and Services 34
7.2.3 CNS Portfolio 35
7.3 Dainippon Sumitmo Pharma 35
7.3.1 Company Overview 35
7.3.2 Financial Performance 35
7.3.3 Business Description 36
7.4 Repligen Corporation 37
7.4.1 Company Overview 37
7.4.2 Financial Performance 37
7.4.3 CNS Portfolio 38
7.5 Cephalon 38
7.5.1 Company Overview 38
7.5.2 Financial Performance 38
7.5.3 Business Description 38
7.5.4 CNS Portfolio 39
7.6 Gedeon Richter Plc. 40
7.6.1 Company Overview 40
7.6.2 Financial Performance 40
7.6.3 Business Description 40
7.6.4 CNS Portfolio 42

8 Global Bipolar Disorder Market: Appendix 43
8.1 Definitions 43
8.2 Scope of Pipeline Research 43
8.3 Acronyms 43
8.4 Research Methodology 44
8.4.1 Coverage 44
8.4.2 Secondary Research 44
8.4.3 Forecasting 45
8.4.4 Primary Research 48
8.4.5 Expert Panel validation 48
8.5 Contact Us 48
8.6 Disclaimer 48
8.7 Sources 49

List of Table


Table 1: Bipolar Disorder, Global, Market Revenue ($m), 20012009 9
Table 2: Bipolar Disorder, Global, Market Forecast ($m), 20092017 9
Table 3: Major Marketed Products Comparison in the Bipolar Disorder Market, 2009 22
Table 4: Bipolar Disorder Therapeutics Most Promising Drugs Under Clinical Development, 2010 26
Table 5: Bipolar Disorder Therapeutics Phase III Clinical Pipeline, 2009 31
Table 6: Bipolar Disorder Therapeutics Phase II Clinical Pipeline, 2009 31
Table 7: Bipolar Disorder Therapeutics Phase I Clinical Pipeline, 2009 32
Table 8: Bipolar Disorder Therapeutics Preclinical Clinical Pipeline, 2009 32
Table 9: Johnson & Johnson CNS Marketed Products, 2009 35
Table 10: Johnson & Johnson CNS Pipeline Products, 2009 35
Table 11: Dainippon Sumitomo CNS Marketed Products, 2009 36
Table 12: Dainippon Sumitomo CNS Pipeline Products, 2009 37
Table 13: Repligen Corporation CNS Pipeline Products, 2009 38
Table 14: Cephalon CNS Marketed Products, 2009 39
Table 15: Cephalon CNS Pipeline Products, 2009 40
Table 16: Geodeon Richter CNS Marketed Products, 2009 42
Table 17: Geodeon Richter CNS Pipeline Products, 2009 42

List of Chart


Figure 1: Bipolar Disorder, Global, Market Revenue ($m) 20012009 8
Figure 2: Bipolar Disorder, Global, Market Forecast ($bn), 20092017 9
Figure 3: Opportunity and Unmet Need in the Bipolar Disorder Market, 2009 11
Figure 4: Strategic Competitor Assessment of the Bipolar Disorder Market, 2010 13
Figure 5: Technology Trends Analytic Framework of Bipolar Disorder Pipeline, 2010 24
Figure 6: Technology Trends Analytic Framework of Bipolar Disorder Description, 2010 25
Figure 7: Bipolar Disorder Therapeutics Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8: Bipolar Disorder Therapeutics Clinical Pipeline by Phase of Clinical Development, 2010 30
Figure 9: Implications For Future Market Competition in the Bipolar Disorder Market, 2010 33
Figure 10: Bipolar Disorder Therapeutics Market Pipeline by Company 34
Figure 11: GlobalData Market Forecasting Model 47

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *